Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy

Mechanisms of chimeric antigen receptor (CAR) T cell–mediated antitumor immunity and toxicity remain poorly characterized because few studies examine the intact tumor microenvironment (TME) following CAR T cell infusion. Axicabtagene ciloleucel is an autologous anti-CD19 CAR T cell therapy approved...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JCI Insight
Asıl Yazarlar: Chen, Pei-Hsuan, Lipschitz, Mikel, Weirather, Jason L., Jacobson, Caron, Armand, Philippe, Wright, Kyle, Hodi, F. Stephen, Roberts, Zachary J., Sievers, Stuart A., Rossi, John, Bot, Adrian, Go, William, Rodig, Scott J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2020
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7406247/
https://ncbi.nlm.nih.gov/pubmed/32484797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.134612
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller